Get the Stockscreener App
6.74
0.44%
-0.03
After Hours:
6.72
-0.02
-0.30%
Monopar Therapeutics Inc stock is traded at $6.74, with a volume of 636.56K.
It is down -0.44% in the last 24 hours and up +182.01% over the past month.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicin for the treatment of soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.
See More
Previous Close:
$6.77
Open:
$7.14
24h Volume:
636.56K
Relative Volume:
0.78
Market Cap:
$23.23M
Revenue:
-
Net Income/Loss:
$-9.48M
P/E Ratio:
-8.7532
EPS:
-0.77
Net Cash Flow:
$-7.61M
1W Performance:
+54.23%
1M Performance:
+182.01%
6M Performance:
+889.72%
1Y Performance:
+987.27%
1-Day Range:
$6.07
$7.18
1-Week Range:
$4.12
$7.18
52-Week Range:
$0.2739
$7.18
Monopar Therapeutics Inc Stock (MNPR) Company Profile
Name
Monopar Therapeutics Inc
Sector
Industry
Phone
(847) 388-0349
Address
1000 SKOKIE BLVD SUITE 350, WILMETTE
Monopar Therapeutics Inc Stock (MNPR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-28-21 | Initiated | ROTH Capital | Buy |
Monopar Therapeutics Inc Stock (MNPR) Latest News
Monopar Therapeutics Inc: A Year of Highs, Lows, and Market Resilience - The InvestChronicle
Analysts review Monopar Therapeutics Inc’s rating - Knox Daily
Monopar Therapeutics Inc (MNPR) Stock: A Year of Market Movement, Down and Up - The InvestChronicle
MNPR Stock Sees Surge of Approximately 31.22% in Last Five Days - Knox Daily
Logos Global Management LP Has $2.95 Million Position in Neumora Therapeutics, Inc. (NASDAQ:NMRA) - Defense World
Monolithic Power Systems, Inc. (NASDAQ:MPWR) Shares Purchased by Xponance Inc. - Defense World
Pacer Advisors Inc. Acquires 684 Shares of Monolithic Power Systems, Inc. (NASDAQ:MPWR) - Defense World
Profund Advisors LLC Purchases 561 Shares of Monolithic Power Systems, Inc. (NASDAQ:MPWR) - Defense World
Bridges Investment Management Inc. Makes New $303,000 Investment in Monolithic Power Systems, Inc. (NASDAQ:MPWR) - Defense World
Westwood Holdings Group Inc. Has $8.63 Million Stock Position in Monolithic Power Systems, Inc. (NASDAQ:MPWR) - Defense World
Mercer Global Advisors Inc. ADV Buys 232 Shares of Monolithic Power Systems, Inc. (NASDAQ:MPWR) - Defense World
Monolithic Power Systems, Inc. (NASDAQ:MPWR) Shares Bought by Dimensional Fund Advisors LP - Defense World
Monolithic Power Systems, Inc. (NASDAQ:MPWR) Shares Sold by Inspire Investing LLC - Defense World
WINTON GROUP Ltd Makes New $633,000 Investment in Monolithic Power Systems, Inc. (NASDAQ:MPWR) - MarketBeat
Monopar Therapeutics Inc (MNPR)’s stock price range in the last year - US Post News
Why Monopar Therapeutics (MNPR) Stock Is Skyrocketing Today - MSN
Monopar Announces Positive Early Human Clinical Data Validating the Tumor Targeting Ability of MNPR-101-Zr - BioSpace
Monopar Shares Rise After Clinical Data on Cancer Treatment - MarketWatch
Summit Therapeutics Secures $235 Million in Funding from Leading Biotech Investors - BP Journal
Monopar Therapeutics' (MNPR) MNPR-101-Zr Shows Promising Tumor Targeting in Early Clinical Trial - BP Journal
Monopar reports positive early results in cancer imaging trial - Investing.com
Monopar (MNPR) Shares Surge As Market Responds To Encouraging Trial Data - Stocks Telegraph
Monopar reports positive early results in cancer imaging trial By Investing.com - Investing.com Australia
Monopar Therapeutics Reports Positive MNPR-101-Zr Trial Results - TipRanks
Monopar reports positive early results in cancer imaging trial By Investing.com - Investing.com UK
Monopar Announces Positive Early Human Clinical Data Validating the Tumor Targeting Ability of MNPR-101-Zr - GlobeNewswire
Monopar to Participate in the H.C. Wainwright 26th Annual Global Investment Conference - Marketscreener.com
MNPRMonopar Therapeutics Inc. Latest Stock News & Market Updates - StockTitan
Monopar Regains Compliance with Nasdaq Minimum Bid Price Rule - GlobeNewswire
Monopar Regains Compliance with Nasdaq Minimum Bid Price Rule - StockTitan
A company insider recently bought 20,508 shares of Monopar Therapeutics Inc [MNPR]. Should You Buy? - Knox Daily
Monopar’s MNPR-101-Lu receives Australian HREC clearance for trial in advanced cancers - BioWorld Online
Monopar Therapeutics Inc Inc. (MNPR) Price Performance: The Role of Share Buybacks and Stock Splits - The InvestChronicle
MNPR’s price-to-cash ratio: Is it a good investment at the moment? - US Post News
Monopar begins phase 1 trial of cancer treatment in Australia - Investing.com
Monopar Receives Clearance to Proceed with Phase 1 Therapeutic Trial of Novel Radiopharmaceutical in - Daily Guardian Canada
Monopar Receives Clearance to Proceed with Phase 1 - GlobeNewswire
Monopar Receives Clearance to Proceed with Phase 1 Therapeutic Trial of Novel Radiopharmaceutical in Advanced Cancers - StockTitan
Monopar Therapeutics Inc. to Post Q4 2024 Earnings of ($0.41) Per Share, Brookline Capital Management Forecasts (NASDAQ:MNPR) - Defense World
Monopar Therapeutics (FRA:1IY0) EV-to-Revenue : (As of Aug. 16, 2024) - GuruFocus.com
HC Wainwright Increases Monopar Therapeutics (NASDAQ:MNPR) Price Target to $6.00 - Defense World
Monopar Therapeutics target adjusted to $9 from $2 at JonesResearch - TipRanks
Monopar Therapeutics (STU:1IY0) Debt-to-Equity : 0.00 (As of Jun. 2024) - GuruFocus.com
Monopar Therapeutics (STU:1IY0) EV-to-Revenue : (As of Aug. 15, 2024) - GuruFocus.com
Research Analysts Set Expectations for Monopar Therapeutics Inc.’s Q3 2024 Earnings (NASDAQ:MNPR) - Defense World
Monopar Therapeutics Inc. (NASDAQ:MNPR) Expected to Earn Q1 2025 Earnings of ($2.75) Per Share - Defense World
Monopar Therapeutics Begins Phase 1 Trial of MNPR-101-Zr - TipRanks
Monopar Announces Initial Data for First Patient Dosed in Radiopharma Phase 1 Clinical Trial of MNPR-101-Zr - GlobeNewswire
Monopar Announces Initial Data for First Patient Dosed in Radiopharma Phase 1 Clinical Trial of MNPR-101-Zr - Yahoo Finance
Monopar Therapeutics Inc (MNPR) may enjoy gains as insiders got busy in the recent days - Knox Daily
We Think Monopar Therapeutics (NASDAQ:MNPR) Needs To Drive Business Growth Carefully - Simply Wall St
Monopar Therapeutics Inc Stock (MNPR) Financials Data
Revenue
Net Income
Cash Flow
EPS
Monopar Therapeutics Inc Stock (MNPR) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Cittadine Andrew | Chief Operating Officer |
Jun 18 '24 |
Buy |
0.86 |
12,000 |
10,320 |
165,624 |
| Cittadine Andrew | Chief Operating Officer |
Jun 14 '24 |
Buy |
0.93 |
12,000 |
11,176 |
141,624 |
| Cittadine Andrew | Chief Operating Officer |
Jun 13 '24 |
Buy |
0.91 |
12,000 |
10,920 |
129,624 |
| Cittadine Andrew | Chief Operating Officer |
Jun 17 '24 |
Buy |
0.90 |
12,000 |
10,799 |
153,624 |
| Cittadine Andrew | Chief Operating Officer |
Jun 04 '24 |
Buy |
0.78 |
12,000 |
9,360 |
117,624 |
| Cittadine Andrew | Chief Operating Officer |
Jun 03 '24 |
Buy |
0.76 |
12,000 |
9,120 |
105,624 |
| Cittadine Andrew | Chief Operating Officer |
May 31 '24 |
Buy |
0.64 |
12,000 |
7,732 |
93,624 |
| Cittadine Andrew | Chief Operating Officer |
May 30 '24 |
Buy |
0.64 |
12,000 |
7,676 |
81,624 |
| Cittadine Andrew | Chief Operating Officer |
May 29 '24 |
Buy |
0.64 |
12,000 |
7,643 |
69,624 |
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):